Curative Biotechnology, Inc. (CUBT)
USD 0.01
(5.93%)
USD 0.01
(5.93%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 5.74 Million USD | -74.6% |
| 2022 | 22.61 Million USD | 20.48% |
| 2021 | 18.77 Million USD | 176.26% |
| 2020 | 6.79 Million USD | 1611.33% |
| 2019 | 397.1 Thousand USD | -45.93% |
| 2018 | 734.35 Thousand USD | 2.23% |
| 2017 | 718.32 Thousand USD | 2.28% |
| 2016 | 702.29 Thousand USD | 2.2% |
| 2015 | 687.15 Thousand USD | -28.5% |
| 2014 | 960.99 Thousand USD | 3.04% |
| 2013 | 932.65 Thousand USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 5.9 Million USD | 2.79% |
| 2024 Q2 | 6.19 Million USD | 4.89% |
| 2023 Q2 | 5.49 Million USD | -72.58% |
| 2023 Q3 | 6.12 Million USD | 11.43% |
| 2023 Q1 | 20.04 Million USD | -11.38% |
| 2023 FY | 5.74 Million USD | -74.6% |
| 2023 Q4 | 5.74 Million USD | -6.17% |
| 2022 Q2 | 20.01 Million USD | 5.96% |
| 2022 Q4 | 22.61 Million USD | 7.06% |
| 2022 Q3 | 21.12 Million USD | 5.58% |
| 2022 FY | 22.61 Million USD | 20.48% |
| 2022 Q1 | 18.88 Million USD | 0.6% |
| 2021 Q1 | 75.37 Thousand USD | -98.89% |
| 2021 FY | 18.77 Million USD | 176.26% |
| 2021 Q4 | 18.77 Million USD | 7245.63% |
| 2021 Q3 | 255.57 Thousand USD | 22.74% |
| 2021 Q2 | 208.22 Thousand USD | 176.26% |
| 2020 Q4 | 6.79 Million USD | 13653.23% |
| 2020 Q1 | 32.13 Thousand USD | -91.91% |
| 2020 Q2 | 32.18 Thousand USD | 0.16% |
| 2020 FY | 6.79 Million USD | 1611.33% |
| 2020 Q3 | 49.41 Thousand USD | 53.53% |
| 2019 Q4 | 397.1 Thousand USD | 0.0% |
| 2019 FY | 397.1 Thousand USD | -45.93% |
| 2018 FY | 734.35 Thousand USD | 2.23% |
| 2017 FY | 718.32 Thousand USD | 2.28% |
| 2016 FY | 702.29 Thousand USD | 2.2% |
| 2015 FY | 687.15 Thousand USD | -28.5% |
| 2014 Q1 | 963.51 Thousand USD | 3.31% |
| 2014 FY | 960.99 Thousand USD | 3.04% |
| 2013 Q1 | 874.49 Thousand USD | 0.0% |
| 2013 Q4 | 932.65 Thousand USD | 0.0% |
| 2013 FY | 932.65 Thousand USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -20844.924% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 39.3% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 92.072% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -610.418% |
| Rebus Holdings, Inc. | 5.24 Million USD | -9.611% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 90.264% |
| Qrons Inc. | 1.48 Million USD | -285.959% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -368.583% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 92.331% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -12755.336% |
| Skye Bioscience, Inc. | 14.07 Million USD | 59.169% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 89.221% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 40.035% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -1262.964% |
| SQZ Biotechnologies Company | 50.03 Million USD | 88.517% |
| Intellipharmaceutics International Inc. | 12 Million USD | 52.153% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -49.187% |
| Mesoblast Limited | 188.44 Million USD | 96.951% |
| Marizyme, Inc. | 26.67 Million USD | 78.46% |
| Genus plc | 485 Million USD | 98.815% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 1.657% |
| Pharming Group N.V. | 244.07 Million USD | 97.646% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -185.843% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -128.341% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -51.206% |
| ContraFect Corporation | 32.53 Million USD | 82.337% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -190.001% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -50.114% |
| IMV Inc. | 37.93 Million USD | 84.853% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 51.216% |
| MultiCell Technologies, Inc. | 1617.67 USD | -355091.17% |
| ONE Bio Corp. | 27.49 Million USD | 79.103% |
| Accustem Sciences Inc. | 1.07 Million USD | -432.396% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 92.578% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -171.661% |
| Q BioMed Inc. | 8.13 Million USD | 29.351% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 93.072% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -11.655% |
| Biomind Labs Inc. | 1.49 Million USD | -283.41% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 95.16% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 36.455% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 68.779% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -300.724% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -3943.648% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -2756.969% |
| GB Sciences, Inc. | 5.41 Million USD | -6.059% |
| Alpha Cognition Inc. | 7.16 Million USD | 19.805% |
| HST Global, Inc. | 593.59 Thousand USD | -867.973% |
| CSL Limited | 18.62 Billion USD | 99.969% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -356.31% |
| Halberd Corporation | 728.71 Thousand USD | -688.482% |
| Enzolytics Inc. | 365.26 Million USD | 98.427% |
| Agentix Corp. | 2.51 Million USD | -128.867% |
| Resverlogix Corp. | 67.39 Million USD | 91.475% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -585.06% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 444.95 Million USD | 98.709% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -235.229% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 76.781% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 51.728% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -56.768% |
| AVAX Technologies, Inc. | 3.99 Million USD | -43.871% |
| Zenith Capital Corp. | 27.56 Thousand USD | -20741.601% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.567% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -2307.595% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -53.866% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -743.939% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -111.895% |
| Kadimastem Ltd | 3.5 Million USD | -63.938% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -8484.95% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 88.569% |
| BioStem Technologies, Inc. | 15.9 Million USD | 63.873% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -1136.461% |
| LadRx Corporation | 2.2 Million USD | -161.111% |
| Cell Source, Inc. | 15.8 Million USD | 63.649% |
| Regen BioPharma, Inc. | 5.45 Million USD | -5.281% |
| Regen BioPharma, Inc. | 5.45 Million USD | -5.281% |
| NovAccess Global Inc. | 7.86 Million USD | 26.905% |
| Affymax, Inc. | 8.87 Million USD | 35.229% |
| Itoco Inc. | 1.65 Million USD | -247.568% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -180.07% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 5.012% |
| Mobile Lads Corp. | 1.31 Million USD | -337.445% |
| CytoDyn Inc. | 127.89 Million USD | 95.507% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -13646.312% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -266.822% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 47.979% |
| SYBLEU INC | 681.41 Thousand USD | -743.222% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 5.836% |
| International Stem Cell Corporation | 5.27 Million USD | -8.884% |
| Bioxytran, Inc. | 3.24 Million USD | -76.822% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -818.143% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -24.446% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 85.984% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 74.193% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -183.69% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -4.889% |
| Neutra Corp. | 973.52 Thousand USD | -490.205% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 80.197% |
| PureTech Health plc | 125.58 Million USD | 95.425% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -52.931% |
| IXICO plc | 1.9 Million USD | -202.365% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 72.011% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 94.439% |
| CSL Limited | 18.62 Billion USD | 99.969% |
| Cellectis S.A. | 249.36 Million USD | 97.696% |